Esophageal Cancer is cancer that forms in tissues lining the esophagus (the muscular tube through which food passes from the throat to the stomach). Two types of esophageal cancer are squamous cell carcinoma (cancer that begins in flat cells lining the esophagus) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids).
Cancerous tumors are made up of many more components than just malignant cells from the tissue of origin. Immune cells can be recruited to the tumor site and form what is known as the tumor microenvironment.
New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival. (1-3)
Globally, esophageal cancer is said to be the eighth most common cancer and it usually develops from a condition known as Barrett’s esophagus.
Non-white Americans, especially Asian Americans, are at disproportionately higher risk for gastric cancer compared to non-Hispanic white Americans.
Biomedical engineers at Duke University have engineered a method for simultaneously detecting the presence of multiple specific microRNAs in RNA extracted from tissue samples without the need for labeling or target amplification.
Baylor Scott & White Research Institute has received funding for a study from the National Institute of Biomedical Imaging and Bioengineering, one of the 27 institutes and centers of the National Institutes of Health (NIH), the nation's premier medical research agency.
The incidence of esophageal adenocarcinoma has increased 8-fold over the past 50 years. This is one of the deadliest cancers, with a five-year survival rate of only 20 percent.
Cancers arise when the genetic code of normal cells is altered, causing excessive growth. Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have discovered a protein that drives the growth of cancers of the esophagus or liver by altering the genetic code in a novel way.